HAS NO ENERGY; LEGS WERE ACHEY; CONSTIPATION; This is a spontaneous report from a contactable consumer, based on information received by Pfizer from Eisai (manufacturer control number: EC-2021-089611), for Covid-19 vaccine. A female patient of an unspecified age received bnt162b2 (BNT162B2), via an unspecified route of administration on 08Mar2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation; amlodipine besilate (AMLODIPINE BESILATE), route of administration, start and stop date, batch/lot number and dose were not reported for an unspecified indication; doxazosin mesilate (DOXAZOSIN MESILATE), route of administration, start and stop date, batch/lot number and dose were not reported for an unspecified indication; metoprolol tartrate (METOPROLOL TARTRATE), route of administration, start and stop date, batch/lot number and dose were not reported for an unspecified indication; spironolactone (SPIRONOLACTONE), route of administration, start and stop date, batch/lot number and dose were not reported for an unspecified indication; lenvatinib mesilate (LENVIMA), oral from 02Mar2021 (Batch/Lot Number: 9848181; Expiration Date: 28Feb2023) to an unspecified date, at 20 mg, daily for endometrial cancer; warfarin (WARFARIN), route of administration, start and stop date, batch/lot number and dose were not reported for an unspecified indication; potassium chloride (KLOR-CON), route of administration, start and stop date, batch/lot number and dose were not reported for an unspecified indication; macrogol 3350 (MIRALAX), route of administration, start and stop date, batch/lot number and dose were not reported for an unspecified indication  .  Medical history included Cancer of breast/axillary tail of breast from an unknown date and unknown if ongoing , hypertension from an unknown date and unknown if ongoing , hypercholesterolaemia from an unknown date and unknown if ongoing , cardiac dysrhythmia from an unknown date and unknown if ongoing , Supraventricular premature beats from an unknown date and unknown if ongoing , Ventricular premature depolarization from an unknown date and unknown if ongoing , First degree Atrioventricular block from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported.  The patient previously took enalapril maleate and experienced allergy, maxzide and experienced allergy, prinivil and experienced allergy.  The patient experienced has no energy on 12Mar2021 with outcome of recovered , legs were achey on 11Mar2021 with outcome of recovered , constipation on Mar2021 with outcome of recovered. Patient reports, Today (03/12/21), she has no energy, and yesterday (03/11/12), her legs were achey, she thinks it might be due to the covid-19 vaccine she had on Monday (03/08/2021). She also reports, she had constipation once this week, and took miralax. The action taken in response to the events for amlodipine besilate was unknown , for doxazosin mesilate was unknown , for metoprolol tartrate was unknown , for spironolactone was unknown , for lenvatinib mesilate was unknown , for warfarin was unknown , for potassium chloride was unknown , for macrogol 3350 was unknown.  Therapeutic measures were taken as a result of constipation (constipation).  Pfizer is a marketing authorization holder of amlodipine besilate, doxazosin mesilate, metoprolol tartrate and spironolactone in the country of incidence or the country where the product was purchased (if different). This may be a duplicate report if another marketing authorization holder of amlodipine besilate, doxazosin mesilate, metoprolol tartrate and spironolactone has submitted the same report to the regulatory authorities.  No follow-up attempts are possible; information about batch number cannot be obtained.